Related Experiment Video
Updated: Jul 24, 2025
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Cancer/testis antigens: promising immunotherapy targets for digestive tract cancers
Huihan Ai1, Hang Yang1, Liang Li1
1Department of General Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China.
Abstract:
Digestive tract cancers, including esophageal, gastric, and colorectal cancers, are the major cause of death among cancer patients worldwide due to the heterogeneity of cancer cells, which limits the effectiveness of traditional treatment methods. Immunotherapy represents a promising treatment strategy for improving the prognosis of patients with digestive tract cancers. However, the clinical application of this approach is limited by the absence of optimal targets. Cancer/testis antigens are characterized by low or absent expression in normal tissues, but high expression in tumor tissues, making them an attractive target for antitumor immunotherapy. Recent preclinical trials have shown promising results for cancer/testis antigen-targeted immunotherapy in digestive cancer. However, practical problems and difficulties in clinical application remain. This review presents a comprehensive analysis of cancer/testis antigens in digestive tract cancers, covering their expression, function, and potential as an immunotherapy target. Additionally, the current state of cancer/testis antigens in digestive tract cancer immunotherapy is discussed, and we predict that these antigens hold great promise as an avenue for breakthroughs in the treatment of digestive tract cancers.
Insights
Cancer/testis antigens show promise for improving digestive tract cancer immunotherapy. Targeting these antigens offers a potential breakthrough for treating esophageal, gastric, and colorectal cancers.
Area of Science:
- Oncology
- Immunology
Background:
- Digestive tract cancers are a leading cause of cancer mortality globally.
- Cancer cell heterogeneity limits traditional treatment efficacy.
- Immunotherapy offers a promising strategy, but requires optimal targets.
Purpose of the Study:
- To comprehensively analyze cancer/testis antigens in digestive tract cancers.
- To evaluate their expression, function, and potential as immunotherapy targets.
- To discuss the current status and future prospects of cancer/testis antigen-targeted immunotherapy.
Main Methods:
- Review of preclinical data and clinical trial outcomes.
- Analysis of cancer/testis antigen expression patterns in normal and tumor tissues.
- Discussion of functional roles and therapeutic implications.
Main Results:
- Cancer/testis antigens exhibit tumor-specific expression, making them ideal targets.
- Preclinical studies demonstrate promising results for targeted immunotherapy.
- Challenges in clinical application and practical difficulties persist.
Conclusions:
- Cancer/testis antigens represent a significant and promising target for novel immunotherapies.
- Further research and clinical development are needed to overcome existing challenges.
- These antigens hold great potential for breakthroughs in digestive cancer treatment.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:17The Tumor Microenvironment